OBS'CEREVANCE: French Cohort of Pediatric Autoimmune Cytopenia

Launched by UNIVERSITY HOSPITAL, BORDEAUX · Jul 7, 2023

Keywords

ClinConnect Summary

The OBS'CEREVANCE trial is studying three specific blood disorders in children: Immune Thrombocytopenia (ITP), Autoimmune Hemolytic Anemia (AIHA), and Evans Syndrome. These conditions occur when the body’s immune system mistakenly attacks its own blood cells, leading to low blood cell counts. This trial involves a large group of pediatric patients across 30 hospitals in France and aims to better understand the long-term health outcomes of these patients, the different genetic factors that may be involved, and how effective various treatments, including new targeted therapies, are.

To be eligible for this study, participants must have been diagnosed with one of these blood disorders before they turned 18. There are no restrictions based on gender, and the study is currently looking for new participants. If your child joins the trial, they will be part of a comprehensive database that helps researchers gather important information about these diseases and their treatments. It's important to note that participation is voluntary, and parents or guardians can choose not to take part or withdraw at any time.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of ITP, AIHA, Evans Syndrome
• • Onset before the age of 18
• Exclusion Criteria:
• • Opposition of legal representative or to data collection